Bank of America’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$539K Sell
37,177
-11,124
-23% -$129K ﹤0.01% 4856
2025
Q4
$464K Buy
48,301
+18,619
+63% +$178K ﹤0.01% 4948
2025
Q3
$279K Sell
29,682
-1,180
-4% -$11.3K ﹤0.01% 6115
2025
Q2
$327K Sell
30,862
-2,269
-7% -$28.6K ﹤0.01% 5942
2025
Q1
$498K Sell
33,131
-5,087
-13% -$84.6K ﹤0.01% 5652
2024
Q4
$629K Buy
38,218
+3,758
+11% +$74.1K ﹤0.01% 5377
2024
Q3
$851K Sell
34,460
-2,193
-6% -$56.9K ﹤0.01% 5161
2024
Q2
$928K Sell
36,653
-266
-0.7% -$6.89K ﹤0.01% 4946
2024
Q1
$938K Sell
36,919
-19,254
-34% -$466K ﹤0.01% 4969
2023
Q4
$1.27M Sell
56,173
-18,658
-25% -$386K ﹤0.01% 4802
2023
Q3
$1.39M Buy
74,831
+19,186
+34% +$398K ﹤0.01% 4564
2023
Q2
$1.45M Sell
55,645
-2,676
-5% -$71.6K ﹤0.01% 4495
2023
Q1
$1.67M Buy
58,321
+9,854
+20% +$293K ﹤0.01% 4504
2022
Q4
$1.43M Buy
48,467
+7,524
+18% +$214K ﹤0.01% 4550
2022
Q3
$975K Buy
40,943
+16,193
+65% +$373K ﹤0.01% 4920
2022
Q2
$553K Sell
24,750
-3,207
-11% -$71.5K ﹤0.01% 5370
2022
Q1
$702K Sell
27,957
-17,521
-39% -$534K ﹤0.01% 5551
2021
Q4
$1.63M Buy
45,478
+27,049
+147% +$1.08M ﹤0.01% 4765
2021
Q3
$784K Sell
18,429
-239
-1% -$9.84K ﹤0.01% 5288
2021
Q2
$809K Sell
18,668
-19,292
-51% -$822K ﹤0.01% 5062
2021
Q1
$1.55M Buy
37,960
+25,163
+197% +$954K ﹤0.01% 4471
2020
Q4
$579K Sell
12,797
-11,480
-47% -$436K ﹤0.01% 4910
2020
Q3
$859K Buy
24,277
+4,564
+23% +$165K ﹤0.01% 4329
2020
Q2
$744K Buy
19,713
+2,925
+17% +$96.4K ﹤0.01% 4336
2020
Q1
$485K Buy
16,788
+7,577
+82% +$306K ﹤0.01% 4518
2019
Q4
$478K Sell
9,211
-6,906
-43% -$401K ﹤0.01% 5034
2019
Q3
$884K Sell
16,117
-9,509
-37% -$488K ﹤0.01% 4640
2019
Q2
$1.04M Sell
25,626
-13,479
-34% -$491K ﹤0.01% 4538
2019
Q1
$1.18M Buy
39,105
+18,579
+91% +$636K ﹤0.01% 4392
2018
Q4
$690K Buy
20,526
+14,082
+219% +$508K ﹤0.01% 4701
2018
Q3
$272K Buy
6,444
+1,520
+31% +$60.1K ﹤0.01% 5313
2018
Q2
$157K Sell
4,924
-1,801
-27% -$74.2K ﹤0.01% 5549
2018
Q1
$335K Sell
6,725
-5,993
-47% -$339K ﹤0.01% 5079
2017
Q4
$686K Sell
12,718
-5,243
-29% -$290K ﹤0.01% 4730
2017
Q3
$1.04M Sell
17,961
-2,257
-11% -$118K ﹤0.01% 4479
2017
Q2
$997K Sell
20,218
-3,077
-13% -$142K ﹤0.01% 4432
2017
Q1
$1.01M Buy
23,295
+11,511
+98% +$550K ﹤0.01% 4419
2016
Q4
$577K Buy
11,784
+10,729
+1,017% +$496K ﹤0.01% 4720
2016
Q3
$51K Sell
1,055
-141
-12% -$6.96K ﹤0.01% 5723
2016
Q2
$64K Sell
1,196
-2,314
-66% -$109K ﹤0.01% 5727
2016
Q1
$157K Sell
3,510
-209
-6% -$8.48K ﹤0.01% 5269
2015
Q4
$142K Sell
3,719
-3,246
-47% -$124K ﹤0.01% 5571
2015
Q3
$222K Sell
6,965
-8,654
-55% -$302K ﹤0.01% 5278
2015
Q2
$516K Buy
15,619
+11,538
+283% +$412K ﹤0.01% 4675
2015
Q1
$168K Sell
4,081
-5,738
-58% -$232K ﹤0.01% 5038
2014
Q4
$400K Buy
9,819
+6,882
+234% +$269K ﹤0.01% 4822
2014
Q3
$108K Buy
2,937
+2,530
+622% +$109K ﹤0.01% 5942
2014
Q2
$19K Sell
407
-6,668
-94% -$297K ﹤0.01% 7177
2014
Q1
$291K Sell
7,075
-4,880
-41% -$181K ﹤0.01% 5100
2013
Q4
$456K Buy
11,955
+10,284
+615% +$317K ﹤0.01% 4843
2013
Q3
$40K Buy
1,671
+449
+37% +$10.1K ﹤0.01% 6542
2013
Q2
$21K Buy
+1,222
New +$17.6K ﹤0.01% 6934

Other funds holding ANIK

Bank of America's ANIK Position: Q1 2026 in Review

Bank of America reduced its Anika Therapeutics (ANIK) stake by 23% in Q1 2026, selling an estimated $129K and leaving 37,177 shares worth $539K. The position accounts for ﹤0.01% of the portfolio, ranked #4856.

Bank of America first reported a position in ANIK in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.67M in Q1 2023. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Bank of America held 37,177 shares of Anika Therapeutics worth $539K as of Q1 2026.
  • Bank of America sold 11,124 Anika Therapeutics shares in Q1 2026, an estimated $129K.
  • Anika Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4856 holding.
  • Bank of America first reported a position in Anika Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Anika Therapeutics position peaked at $1.67M in Q1 2023.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.